Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).
Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.
For more information, please call the Help Desk at 800-636-0373.
The information contained in this section of the site is intended for US specialty pharmacy representatives only. Click "OK" if you are a specialty pharmacy representative.
With the ENSPRYNG Co-pay Program, eligible, commercially insured patients pay as little as $5 per 30-day supply of ENSPRYNG. The program covers the rest of the patient's out-of-pocket costs, up to $20,000 in assistance per calendar year.
There are no income requirements for the ENSPRYNG Co-pay Program.
*Commercial insurance includes plans you receive from your job or plans from the Health Insurance Marketplace. Government programs like Medicare and Medicaid are not commercial insurance.
If a patient is not eligible for the ENSPRYNG Co-pay Program, there may be other options for co-pay assistance. Call (844) 677-7964 or visit genentech-access.com/ENSPRYNG to learn more.
ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
ENSPRYNG is contraindicated in patients with a known hypersensitivity to satralizumab or any of the inactive ingredients, an active hepatitis B infection, or active or untreated latent tuberculosis.
Infections
Delay ENSPRYNG administration in patients with an active infection until the infection is resolved. Vaccination with live or live attenuated vaccines is not recommended during treatment.
Elevated Liver Enzymes
Monitor ALT and AST levels during treatment; interruption of ENSPRYNG may be required.
Decreased Neutrophil Counts
Monitor neutrophils during treatment.
The most common adverse reactions (≥15% in either trial) were nasopharyngitis (31%), headache (27%), upper respiratory tract infection (19%), rash (17%), arthralgia (17%), extremity pain (15%), gastritis (15%), fatigue (15%), and nausea (15%).
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
For additional safety information, please see the full Prescribing Information and Medication Guide.
We are open from 9 a.m.–8 p.m. ET, Monday through Friday, except for the following holidays:
Questions about this program?
Call (800) 636-0373
9 a.m.–8 p.m. ET, Monday through Friday (except major holidays)
For questions about ENSPRYNG, please call (844) NSPRYNG (844-677-7964).
© 2022 Genentech USA, Inc. So. San Francisco, CA
All rights reserved.
Fax (866)-800-8432
to change word size.